Quantum Computing in Drug Discovery Market Projected to Reach $637.83 Million by 2035

The global market for quantum computing in drug discovery reached $126.11 million in 2025, with projections indicating a significant expansion to $637.83 million by 2035. This growth is expected to occur at a compound annual growth rate (CAGR) of 17.9% between 2026 and 2035, according to analysis by DataM Intelligence. The market is being propelled by increased pharmaceutical research and development investments and advancements in molecular simulation technologies.

Key growth drivers include the rising adoption of quantum-classical hybrid computing, the expansion of cloud-based quantum platforms, and a growing demand for accelerated drug discovery workflows. Quantum computing's ability to provide highly accurate molecular simulations and predict drug-target interactions effectively is enhancing lead identification and optimization processes.

Strategic collaborations between quantum technology providers and pharmaceutical companies, coupled with the increasing availability of cloud-based Quantum-as-a-Service (QaaS) platforms, are expected to further accelerate the adoption of quantum computing in drug discovery. QaaS enables companies to access advanced quantum capabilities without substantial upfront infrastructure investment.

The molecular simulation segment is particularly significant, accounting for approximately 31.3% of the market. North America currently leads the market due to its robust pharmaceutical R&D infrastructure, government funding, and the presence of key quantum technology companies.